Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGattaca Regulatory News (GATC)

Share Price Information for Gattaca (GATC)

Share Price is delayed by 15 minutes
Get Live Data
147.50    -1.50 (-1.01%)
Bid:
145.00
Ask:
150.00
Spread: 5.00 (3.448%)
Market Cap: £45.56m
GATC Live PriceLast checked at - London Stock Exchange

Intraday Gattaca Share Chart

Awards under the Value Creation Plan

21 Nov 2011 09:14

RNS Number : 4413S
Matchtech Group PLC
21 November 2011
 



 

21 November 2011

 

 

MATCHTECH GROUP plc

 

("Matchtech", the "Company" or the "Group")

 

Awards under the Value Creation Plan ("VCP")

 

Matchtech, one of the UK's leading specialist recruitment agencies operating in the Engineering, Science, Technology and Professional Services sectors, announces that awards under the VCP have been made to the directors listed below on 18 November 2011. The VCP was approved by the shareholders in General Meeting on 18 November 2011.

 

The following directors have been conditionally granted an award of units under the VCP:

 

Name

Position

Number of VCP units

Percentage of total number of VCP units allocated and to be allocated

Adrian Gunn

Chief Executive

266,000

26.6%

Tony Dyer

Chief Financial Officer

145,000

14.5%

Other Senior Management

 

412,000

41.2%

Reserved for future allocations

177,000

17.7%

 

No payment has been made for the grant of these awards and the VCP units have no value at grant.

 

The VCP has a five year performance period (ending after the preliminary announcement of the Company's final accounts in 2016) and the VCP units entitle the directors to share in 7.5 per cent. of the total value created for shareholders in excess of an annual hurdle at a series of measurement dates.

 

The level of value created for Matchtech shareholders will be determined by reference to the appreciation in the Company's share price, the amount of dividends paid and share buy backs. The shareholder value created at each measurement date will be calculated using the average share price over the 30-day period prior to the relevant measurement date.

The annual hurdle will be the higher of;

·; the actual share price at the previous measurement date; and

·; 20% growth over the threshold price from the previous Measurement Date.

 

The initial price is 218p per Matchtech share, being the average share price of Matchtech shares for the 30-day period following the preliminary announcement of the Company's 2011 final results. This will results in the first threshold price being 261.6p (218p increased by 20%).

At each measurement date each director will receive an entitlement to Matchtech shares (in the form of a nil-cost option) with a value equivalent to each director's relevant proportion. of the VCP Pool created in respect of that measurement date. Any share entitlement will not become exercisable until the end of the fifth year of the VCP when 50 per cent. of the shares are exercisable, with the balance exercisable one year later.

 

Enquiries:

 

Matchtech Group plc

Adrian Gunn, Chief Executive Officer 01489 898 989

Tony Dyer, Chief Financial Officer

 

MHP Communications 020 3128 8100

John Olsen / Ian Payne / Giles Robinson

 

Arbuthnot Securities 020 7012 2000

James Steel / Tim Willis

 

 

 

END

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKFLBLFFFFFBX
Date   Source Headline
14th May 20267:00 amRNSTrading Update
1st Apr 20267:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Mar 20267:00 amRNSInterim Results
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Feb 20267:00 amRNSTrading Update
31st Dec 20257:00 amRNSDirector/PDMR dealing
31st Dec 20257:00 amRNSDirector/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
16th Dec 202512:19 pmRNSExercise of Options and Director/PDMR Shareholding
11th Dec 20259:05 amRNSResults of Annual General Meeting
10th Nov 20257:00 amRNSAvailability of Report & Accounts and AGM Notice
23rd Oct 20257:00 amRNSFinal results for the year ended 31 July 2025
15th Oct 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
13th Oct 20252:59 pmRNSBlock Listing Six Monthly return
8th Oct 20257:00 amRNSNotice of Results
5th Aug 20257:00 amRNSTrading update and Acquisition
22nd Jul 20257:00 amRNSEBT Share Purchase Programme
21st Jul 20256:22 pmRNSExercise of Options and Director/PDMR Shareholding
2nd Apr 20252:21 pmRNSCORRECTION – Interim Results
2nd Apr 20257:00 amRNSInterim Results
1st Apr 20257:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Feb 20257:00 amRNSTrading Update
27th Jan 20254:51 pmRNSFurther re EBT Share Purchase Programme
11th Dec 20243:59 pmRNSDirector/PDMR Shareholding
11th Dec 20242:25 pmRNSResult of AGM
11th Nov 20242:29 pmRNSAvailability of Report & Accounts and AGM Notice
30th Oct 20247:00 amRNSEBT Share Purchase Programme
24th Oct 20247:00 amRNSFinal results for the year ended 31 July 2024
1st Oct 20247:00 amRNSBlock listing Six Monthly Return
15th Aug 20247:00 amRNSTrading Update for the year ended 31 July 2024
16th Jul 202410:36 amRNSDirector/PDMR Share Purchase
11th Jul 202411:13 amRNSExercise of Options
1st Jul 20247:00 amRNSNominated Adviser and Broker
16th Apr 20247:00 amRNSInterim Results
2nd Apr 20247:00 amRNSBlock listing six monthly return
15th Feb 20247:00 amRNSTrading Update
25th Jan 20247:00 amRNSExercise of Options
6th Dec 20235:07 pmRNSDirector/PDMR Shareholding
6th Dec 20234:51 pmRNSResults of Annual General Meeting
28th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSTransaction in Own Shares
24th Nov 20237:00 amRNSTransaction in Own Shares
22nd Nov 20237:00 amRNSTransaction in Own Shares
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 20237:00 amRNSTransaction in Own Shares
17th Nov 20237:00 amRNSTransaction in Own Shares
15th Nov 20237:00 amRNSTransaction in Own Shares
14th Nov 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.